Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Philipp Harter; Marie Ange Mouret-Reynier; Sandro Pignata; Claire Cropet; Antonio González-Martín; Gerhard Bogner; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Trine Jakobi Nøttrup; Anne Floquet; Ahmed El-Balat; Giovanni Scambia; Eva Maria Guerra Alia; Michel Fabbro; Barbara Schmalfeldt; Anne-Claire Hardy-Bessard; Ingo Runnebaum; Eric Pujade-Lauraine; Isabelle Ray-Coquard

doi:10.1016/j.ygyno.2021.12.016

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Philipp Harter
, Marie Ange Mouret-Reynier
, Sandro Pignata
, Claire Cropet
, Antonio González-Martín
, Gerhard Bogner (Co-author)
, Keiichi Fujiwara
, Ignace Vergote
, Nicoletta Colombo
, Trine Jakobi Nøttrup
, Anne Floquet
, Ahmed El-Balat
, Giovanni Scambia
, Eva Maria Guerra Alia
, Michel Fabbro
, Barbara Schmalfeldt
, Anne-Claire Hardy-Bessard
, Ingo Runnebaum
, Eric Pujade-Lauraine
, Isabelle Ray-Coquard

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Original Article › peer-review

81 Citations (Web of Science)

Original language	English
Pages (from-to)	254-264
Journal	GYNECOLOGIC ONCOLOGY
Volume	164
Issue number	2
DOIs	https://doi.org/10.1016/j.ygyno.2021.12.016
Publication status	Published - 2022

Keywords

GROUPS REQUIREMENTS
EUROPEAN NETWORK
ACADEMIC GROUPS
CHEMOTHERAPY

Access to Document

10.1016/j.ygyno.2021.12.016

Cite this

Harter, P., Mouret-Reynier, M. A., Pignata, S., Cropet, C., González-Martín, A., Bogner, G., Fujiwara, K., Vergote, I., Colombo, N., Nøttrup, T. J., Floquet, A., El-Balat, A., Scambia, G., Guerra Alia, E. M., Fabbro, M., Schmalfeldt, B., Hardy-Bessard, A.-C., Runnebaum, I., Pujade-Lauraine, E., & Ray-Coquard, I. (2022). Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. GYNECOLOGIC ONCOLOGY , 164(2), 254-264. https://doi.org/10.1016/j.ygyno.2021.12.016

Harter, Philipp ; Mouret-Reynier, Marie Ange ; Pignata, Sandro et al. / Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. In: GYNECOLOGIC ONCOLOGY 2022 ; Vol. 164, No. 2. pp. 254-264.

@article{018af5261b95417c8d0adb4067d6660e,

title = "Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.",

keywords = "GROUPS REQUIREMENTS, EUROPEAN NETWORK, ACADEMIC GROUPS, CHEMOTHERAPY",

author = "Philipp Harter and Mouret-Reynier, \{Marie Ange\} and Sandro Pignata and Claire Cropet and Antonio Gonz{\'a}lez-Mart{\'i}n and Gerhard Bogner and Keiichi Fujiwara and Ignace Vergote and Nicoletta Colombo and N{\o}ttrup, \{Trine Jakobi\} and Anne Floquet and Ahmed El-Balat and Giovanni Scambia and \{Guerra Alia\}, \{Eva Maria\} and Michel Fabbro and Barbara Schmalfeldt and Anne-Claire Hardy-Bessard and Ingo Runnebaum and Eric Pujade-Lauraine and Isabelle Ray-Coquard",

note = "Bogner: Paracelsus Medical University Salzburg, Salzburg, and Arbeitsgemeinschaft Gynaekologische Onkologie (AGO Austria), Austria",

year = "2022",

doi = "10.1016/j.ygyno.2021.12.016",

language = "English",

volume = "164",

pages = "254--264",

journal = "GYNECOLOGIC ONCOLOGY ",

issn = "0090-8258",

number = "2",

}

Harter, P, Mouret-Reynier, MA, Pignata, S, Cropet, C, González-Martín, A, Bogner, G, Fujiwara, K, Vergote, I, Colombo, N, Nøttrup, TJ, Floquet, A, El-Balat, A, Scambia, G, Guerra Alia, EM, Fabbro, M, Schmalfeldt, B, Hardy-Bessard, A-C, Runnebaum, I, Pujade-Lauraine, E & Ray-Coquard, I 2022, 'Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.', GYNECOLOGIC ONCOLOGY , vol. 164, no. 2, pp. 254-264. https://doi.org/10.1016/j.ygyno.2021.12.016

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. / Harter, Philipp; Mouret-Reynier, Marie Ange; Pignata, Sandro et al.
In: GYNECOLOGIC ONCOLOGY , Vol. 164, No. 2, 2022, p. 254-264.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

AU - Harter, Philipp

AU - Mouret-Reynier, Marie Ange

AU - Pignata, Sandro

AU - Cropet, Claire

AU - González-Martín, Antonio

AU - Bogner, Gerhard

AU - Fujiwara, Keiichi

AU - Vergote, Ignace

AU - Colombo, Nicoletta

AU - Nøttrup, Trine Jakobi

AU - Floquet, Anne

AU - El-Balat, Ahmed

AU - Scambia, Giovanni

AU - Guerra Alia, Eva Maria

AU - Fabbro, Michel

AU - Schmalfeldt, Barbara

AU - Hardy-Bessard, Anne-Claire

AU - Runnebaum, Ingo

AU - Pujade-Lauraine, Eric

AU - Ray-Coquard, Isabelle

N1 - Bogner: Paracelsus Medical University Salzburg, Salzburg, and Arbeitsgemeinschaft Gynaekologische Onkologie (AGO Austria), Austria

PY - 2022

Y1 - 2022

KW - GROUPS REQUIREMENTS

KW - EUROPEAN NETWORK

KW - ACADEMIC GROUPS

KW - CHEMOTHERAPY

U2 - 10.1016/j.ygyno.2021.12.016

DO - 10.1016/j.ygyno.2021.12.016

M3 - Original Article

C2 - 34952708

SN - 0090-8258

VL - 164

SP - 254

EP - 264

JO - GYNECOLOGIC ONCOLOGY

JF - GYNECOLOGIC ONCOLOGY

IS - 2

ER -

Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. GYNECOLOGIC ONCOLOGY . 2022;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016